Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 3/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28253360 | 0.84 | ACHE (0.51) | KMT2ASMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL4155798 | 0.81 | KMT2A (0.52) | KMT2ASMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL13696882 | 0.81 | CYP1A2 (0.55) | KMT2ASMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL2944297 | 0.80 | PIM1 (0.48) | KMT2ASMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL3364537 | 0.78 | CHRM2 (0.57) | KMT2ASMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL2920813 | 0.77 | KMT2A (0.57) | KMT2ASMN1; SMN2MAPTRAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL11551062 | 0.76 | KMT2A (0.47) | KMT2ASMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL7877715 | 0.75 | CHRM2 (0.80) | KMT2ASMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL7877922 | 0.75 | CHRM2 (0.80) | KMT2ASMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL3458914 | 0.74 | ALDH1A1 (0.65) | KMT2ASMN1; SMN2MAPTRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589961-B2 | For inhibiting metastases of a tumor in a mammal | NEW YORK MEDICAL COLLEGE | 2003-07-08 | — | — | US | claimed |
| EP-1257538-A2 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2002-11-20 | — | — | EP | claimed |
| US-20020099211-A1 | 9-alkylamino-1-nitroacridine derivatives | NEW YORK MEDICAL COLLEGE | 2002-07-25 | — | — | US | claimed |
| WO-2001060801-A2 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2001-08-23 | — | — | WO | claimed |
| CN-108912104-A | It is a kind of for treating the selective PI3K inhibitor of tumour | 王延娇 | 2018-11-30 | — | — | CN | disclosed |
| CN-108864074-A | A kind of application of compound and its alternatively property PI3K inhibitor in treatment tumour | 王延娇 | 2018-11-23 | — | — | CN | disclosed |
| US-9127164-B2 | Fluorescent dyes and uses thereof | ALMAC SCIENCES (SCOTLAND) LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| EP-1940965-B1 | NOVEL FLUORESCENT DYES AND USES THEREOF | ALMAC SCIENCES SCOTLAND LTD (GB) | 2014-03-26 | — | — | EP | disclosed |
| EP-1257538-B1 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-1261325-B1 | TUMOR INHIBITING COMPOSITIONS COMPRISING NITROACRIDINES | NEW YORK MEDICAL COLLEGE (US) | 2010-09-08 | — | — | EP | disclosed |
| US-7622478-B2 | 1-nitroacridine/tumor inhibitor compositions | TIWARI RAJ | 2009-11-24 | — | — | US | disclosed |
| US-20090226940-A1 | NOVEL FLUORESCENT DYES AND USES THEREOF | ITI SCOTLAND LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| WO-2001060351-A2 | NITROACRIDINE/TUMOR INHIBITOR COMPOSITIONS | NEW YORK MEDICAL COLLEGE (US) | 2001-08-23 | — | — | WO | disclosed |
| WO-2000032175-A2 | METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY | PFIZER PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| US-5348946-A | Heteroanthracycline antitumor analogs | BIOCHEM IMMUNOSYSTEMS, INC. (CA) | 1994-09-20 | — | — | US | disclosed |
| WO-1992015601-A2 | HETEROANTHRACYCLINE ANTITUMOR ANALOGS | BIOCHEM PHARMA, INC. (CA) | 1992-09-17 | — | — | WO | disclosed |
| EP-0502661-A2 | Heteroanthracycline anti-tumor analogues | BIOCHEM PHARMA INC. (CA) | 1992-09-09 | — | — | EP | disclosed |
| US-5141960-A | Central nervous system disorders | G. D. SEARLE & CO. (US) | 1992-08-25 | — | — | US | disclosed |
| US-4462993-A | REACTION WITH A SUGAR IN PRESENCE OF ACID CATALYST | BIOGAL GYOGYSZERGYAR (HU) | 1984-07-31 | — | — | US | disclosed |
| US-4139531-A | ANTINEOPLASTIC | POLITECHNIKA GDANSKA (PL) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226940-A1 | NOVEL FLUORESCENT DYES AND USES THEREOF | ACR, ANXA5, GLB1 | KMT2A 4502/4885SMN1; SMN2 3974/4885MAPT 2114/4885 |
| US-20020099211-A1 | 9-alkylamino-1-nitroacridine derivatives | NPPA, ABCB11, ABCC9 | KMT2A 3892/4885SMN1; SMN2 1577/4885MAPT 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.